KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Other Working Capital Changes (2016 - 2025)

Novavax has reported Other Working Capital Changes over the past 16 years, most recently at -$2.4 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$2.4 million for Q4 2025, down 159.26% from a year ago — trailing twelve months through Dec 2025 was -$622.9 million (down 75.93% YoY), and the annual figure for FY2025 was -$622.9 million, down 75.93%.
  • Other Working Capital Changes for Q4 2025 was -$2.4 million at Novavax, up from -$11.7 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for NVAX hit a ceiling of $1.2 billion in Q3 2021 and a floor of -$809.2 million in Q4 2021.
  • Median Other Working Capital Changes over the past 5 years was -$15.1 million (2023), compared with a mean of -$38.4 million.
  • Peak annual rise in Other Working Capital Changes hit 1612.53% in 2021, while the deepest fall reached 4770.71% in 2021.
  • Novavax's Other Working Capital Changes stood at -$809.2 million in 2021, then soared by 88.4% to -$93.9 million in 2022, then skyrocketed by 355.62% to $240.0 million in 2023, then tumbled by 100.38% to -$913000.0 in 2024, then tumbled by 159.26% to -$2.4 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$2.4 million (Q4 2025), -$11.7 million (Q3 2025), and -$4.9 million (Q2 2025) per Business Quant data.